Cough Syrup Deaths Lead to Stringent Compliance Deadline for Pharmaceutical Firms
Cough Syrup Deaths Prompt Urgent Response
In light of recent cough syrup deaths, the Indian government has mandated that all pharmaceutical manufacturers adhere to international quality standards by January 2025. This directive comes after a disturbing series of fatalities involving over 140 children linked to contaminated cough syrups across Africa and Central Asia.
Central Drugs Standard Control Organisation (CDSCO) Steps In
On Friday, the CDSCO ordered an immediate upgrade of factory facilities to meet WHO-recommended norms. Among these measures are strict protocols for contamination prevention and enhanced batch-level testing. Following the tragic death of 24 children in central India due to a contaminated cough syrup, the CDSCO has refused industry pleas for more time and instead has prioritized immediate compliance.
- The CDSCO will apply revised manufacturing norms starting January 1.
- Strict inspections will be implemented to ensure adherence.
- Failure to comply may result in severe penalties.
While major pharmaceutical companies have complied with previous deadlines, smaller manufacturers are now at risk of significant operational setbacks. An association representing these companies cautioned that without extensions, many could face shutdowns, which would likely result in both job losses and higher prices for medicines.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.